glp-1 urinary tract infection GLP1 Medications and Risks Explained GLP-1 receptor agonists and next-generation

External or subjective effects are not yet visible

In the STEP 1 trial, nausea, diarrhoea, vomiting or constipation affected around 74% of people on semaglutide, compared with about 48% on placebo, and a small number stopped treatment because of side effects

Retatrutide is investigational globally as of April 2026 and should be handled only within appropriate research protocols

Orforglipron is currently in clinical trials and Eli Lilly is requesting a voucher from the FDA to speed up review of the pill, the officials noted

S., Mani, H., Banaudha, K., Maheshwari, R

Why medication is often needed alongside lifestyle changes You have been eating less carbs